Role of stem cells in melanoma progression: Hopes for a better treatment

Expert Review of Dermatology

Volumn 2, Issue 2, 2007, Pages 191-201

  Zabierowski, Susan E ^a   Herlyn, Meenhard ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

cancer stem cells; melanocyte stem cells; melanocytes; melanoma; melanoma stem like cells; niche; self renewal; targeted therapy

Indexed keywords

EID: 85018894456     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.2.2.191     Document Type: Article

References (75)

1. Kelly JW, Yeatman JM, Regalia C, Mason G, Henham AP. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med. J. Aust. 167, 191–194 (1997).
2. Berwick M, Wiggins C. The current epidemiology of cutaneous malignant melanoma. Front Biosci. 11, 1244–1254 (2006).
3. Sharpe G. Skin cancer: prevalence, prevention and treatment. Clin. Med. 6, 333–334 (2006).
4. Queirolo P, Acquati M, Kirkwood JM et al. Update: current management issues in malignant melanoma. Melanoma Res. 15, 319–324 (2005).
5. Young SE, Martinez SR, Essner R. The role of surgery in treatment of stage IV melanoma. J. Surg. Oncol. 94, 344–351 (2006).
6. Mutter N, Stupp R. Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev. Anticancer Ther. 6 (8), 1187–1204 (2006).
7. Pilla L, Valenti R, Marrari A et al. Vaccination: role in metastatic melanoma. Expert Rev. Anticancer Ther. 6 (8), 1305–1318 (2006).
8. Herlyn M. Molecular targets in melanoma: strategies and challenges for diagnosis and therapy. Int. J. Cancer 118, 523–526 (2006).
9. Meier F, Schittek B, Busch S et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 10, 2986–3001 (2005).
10. Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62, 6997–7000 (2002).
11. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
12. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 122, 337–341 (2004).
13. Stahl JM, Sharma A, Cheung M et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002–7010 (2004).
14. Flaherty KT. New molecular targets in melanoma. Curr. Opin. Oncol. 16, 150–154 (2004).
15. Becker JC, Kirkwood JM, Agarwala SS et al. Molecularly targeted therapy for melanoma: current reality and future options. Cancer 107, 2317–2327 (2006).
16. Haass NK, Smalley KS, Herlyn M. The role of altered cell–cell communication in melanoma progression. J. Mol. Histol. 35, 309–318 (2004).
17. Hsu MY, Meier FE, Nesbit M et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am. J. Pathol. 156, 1515–1525 (2000).
18. Hirobe T. Role of keratinocyte-derived factors involved in regulating the proliferation and differentiation of mammalian epidermal melanocytes. Pigment. Cell. Res. 18, 2–12 (2005).
19. Berking C, Takemoto R, Satyamoorthy K et al. Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Res. 64, 807–811 (2004).
20. Fukunaga-Kalabis M, Martinez G, Liu ZJ et al. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J. Cell. Biol. 175, 563–569 (2006).
21. Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment. Cell. Res. 18, 150–159 (2005).
22. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch. Dermatol. 139, 1620–1624 (2003).
23. Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 441, 1068–1074 (2006).
24. Conboy IM, Rando TA. The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. Dev. Cell 3, 397–409 (2002).
25. Cayouette M, Raff M. Asymmetric segregation of Numb: a mechanism for neural specification from Drosophila to mammals. Nat. Neurosci. 5, 1265–1269 (2002).
26. Siegrist SE, Doe CQ. Extrinsic cues orient the cell division axis in Drosophila embryonic neuroblasts. Development 133, 529–536 (2006).
27. Zhang R, Zhang Z, Zhang C et al. Stroke transiently increases subventricular zone cell division from asymmetric to symmetric and increases neuronal differentiation in the adult rat. J. Neurosci. 24, 5810–5815 (2004).
28. Morrison SJ, Hemmati HD, Wandycz AM, Weissman IL. The purification and characterization of fetal liver hematopoietic stem cells. Proc. Natl Acad. Sci. USA 92, 10302–10306 (1995).
29. Nishimura EK, Jordan SA, Oshima H et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 416, 854–860 (2002).
30. Tumbar T, Guasch G, Greco V et al. Defining the epithelial stem cell niche in skin. Science 303, 359–363 (2004).
31. Amoh Y, Li L, Katsuoka K, Penman S, Hoffman RM. Multipotent nestin-positive, keratin-negative hair-follicle bulge stem cells can form neurons. Proc. Natl Acad. Sci. USA 102, 5530–5534 (2005).
32. Yu H, Fang D, Kumar SM et al. Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am. J. Pathol. 168, 1879–1888 (2006).
33. Lang D, Lu MM, Huang L et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433, 884–887 (2005).
34. Osawa M, Egawa G, Mak SS et al. Molecular characterization of melanocyte stem cells in their niche. Development 132, 5589–5599 (2005).
35. Nishimura EK, Granter SR, Fisher DE. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science 307, 720–724 (2005).
36. Mak SS, Moriyama M, Nishioka E, Osawa M, Nishikawa S. Indispensable role of Bcl2 in the development of the melanocyte stem cell. Dev. Biol. 291, 144–153 (2006).
37. Moriyama M, Osawa M, Mak SS et al. Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J. Cell. Biol. 173, 333–339 (2006).
38. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 124, 1111–1115 (2006).
39. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea – a paradigm shift. Cancer Res. 66, 1883–1890 (2006).
40. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res. 14, 213–222 (1961).
41. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821–5828 (2003).
42. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111–115 (2007).
43. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104, 973–978 (2007).
44. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 (2007).
45. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).
46. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003).
47. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65, 9328–9337 (2005).
48. Grichnik JM, Burch JA, Schulteis RD et al. Melanoma, a tumor based on a mutant stem cell? J. Invest. Dermatol. 126, 142–153 (2006).
49. Clarke MF. Oncogenes, self-renewal and cancer. Pathol. Biol. (Paris) 54, 109–111 (2006).
50. Molofsky AV, Pardal R, Iwashita T et al. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425, 962–967 (2003).
51. Park IK, Qian D, Kiel M et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302–305 (2003).
52. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255–260 (2003).
53. Kim CF, Jackson EL, Woolfenden AE et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823–835 (2005).
54. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 432, 324–331 (2004).
55. Dontu G, Jackson KW, McNicholas E et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 6, R605 –R615 (2004).
56. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
57. Balint K, Xiao M, Pinnix CC et al. Activation of Notch1 signaling is required for β-catenin-mediated human primary melanoma progression. J. Clin. Invest. 115, 3166–3176 (2005).
58. Li L, Xie T. Stem cell niche: structure and function. Annu. Rev. Cell. Dev. Biol. 21, 605–631 (2005).
59. Lin H. The stem-cell niche theory: lessons from flies. Nat. Rev. Genet. 3, 931–940 (2002).
60. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature 414, 98–104 (2001).
61. Watt FM. Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO J. 21, 3919–3926 (2002).
62. Scadden DT. The stem-cell niche as an entity of action. Nature 441, 1075–1079 (2006).
63. Zhu AJ, Haase I, Watt FM. Signaling via β1 integrins and mitogen-activated protein kinase determines human epidermal stem cell fate in vitro. Proc. Natl Acad. Sci. USA 96, 6728–6733 (1999).
64. Stier S, Ko Y, Forkert R et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J. Exp. Med. 201, 1781–1791 (2005).
65. Garcion E, Halilagic A, Faissner A, ffrench-Constant C. Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. Development 131, 3423–3432 (2004).
66. Smalley KS, Brafford PA, Herlyn M. Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Semin. Cancer Biol. 15, 451–459 (2005).
67. Chiba S. Notch signaling in stem cell systems. Stem Cells 24, 2437–2447 (2006).
68. Pozniak CD, Pleasure SJ. A tale of two signals: Wnt and Hedgehog in dentate neurogenesis. Sci. STKE 2006, pe5 (2006).
69. Rattis FM, Voermans C, Reya T. Wnt signaling in the stem cell niche. Curr. Opin. Hematol. 11, 88–94 (2004).
70. Ross J, Li L. Recent advances in understanding extrinsic control of hematopoietic stem cell fate. Curr. Opin. Hematol. 13, 237–242 (2006).
71. Lowry WE, Blanpain C, Nowak JA et al. Defining the impact of β-catenin/Tcf transactivation on epithelial stem cells. Genes Dev. 19, 1596–1611 (2005).
72. Silva-Vargas V, Lo Celso C, Giangreco A et al. β-catenin and Hedgehog signal strength can specify number and location of hair follicles in adult epidermis without recruitment of bulge stem cells. Dev. Cell 9, 121–131 (2005).
73. Sun TT, Cotsarelis G, Lavker RM. Hair follicular stem cells: the bulge-activation hypothesis. J. Invest. Dermatol. 96, 77S –78S (1991).
74. Smalley KS, Haass NK, Brafford PA et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5, 1136–1144 (2006).
75. Fan X, Matsui W, Khaki L et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 66, 7445–7452 (2006).